Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05611853 Terminated - Clinical trials for Mantle Cell Lymphoma

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: November 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 trial to study the safety, pharmacokinetics and preliminary efficacy of BN301 given intravenously every 3 weeks.

NCT ID: NCT05107856 Terminated - Clinical trials for Acute Myeloid Leukemia

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies. The purpose of this study is to evaluate the safety and tolerability of PRT1419 monotherapy and in combination with either azacitidine or venetoclax, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

NCT ID: NCT04844086 Terminated - Clinical trials for Mantle Cell Lymphoma

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Start date: March 2, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients. Approximately 24 subjects will be enrolled and it is anticipated approximately 16 subjects will be infused at the varied doses of T cells.

NCT ID: NCT04762160 Terminated - Follicular Lymphoma Clinical Trials

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.

NCT ID: NCT04722601 Terminated - Follicular Lymphoma Clinical Trials

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Start date: September 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study focuses on finding a safe and tolerable dose for a three-drug regimen that combines venetoclax (Venclexta Ⓡ), CC-486 (also known as oral azacitidine) and obinutuzumab (Gazyva Ⓡ) to treat cancer participants who have minimally pretreated follicular lymphoma and have experienced disease progression despite trying previous cancer therapies. If a safe and tolerable drug dose can be found in the first phase of the study, doctors leading the study will launch a second phase of the study within an expansion cohort. Participants in this expansion cohort will receive the dose established in the first phase of the study to determine the efficacy of the regimen/ established dose. Participants in the expansion cohort will also receive the same study drugs from the first phase of the study, but in a different order/combination (first pairing the two oral drugs, CC-486 and venetoclax, then adding the third drug, obinutuzumab to treatment). The end goal of this research is to establish a new chemotherapy-sparing treatment option for patients with follicular lymphoma that is just as effective (or better) than current standard of care options.

NCT ID: NCT04590820 Terminated - Lymphoma Clinical Trials

Oral Tazemetostat in Combination With Rituximab in R/R FL

Start date: November 17, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to examine the feasibility and efficacy of adding the EZH2 inhibitor, Tazemetostat to rituixmab, standard second line or beyond therapy as a means to improve disease response.

NCT ID: NCT04358458 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Start date: March 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3009 dose to be tested in a larger group of patients and assess preliminary clinical activity of GEN3009. GEN3009 will be studied in a broad group of cancer patients, having different kinds of lymphomas. All patients will get GEN3009 either as a single treatment (monotherapy) or in combination with another antibody-candidate for treatment of cancer in the blood. The study consists of two parts: Part 1 tests increasing doses of GEN3009 ("escalation"), followed by Part 2 which tests the recommended GEN3009 dose from Part 1 ("expansion").

NCT ID: NCT04342117 Terminated - Lymphoma Clinical Trials

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

REAL
Start date: April 23, 2020
Phase:
Study type: Observational [Patient Registry]

This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.

NCT ID: NCT04176913 Terminated - Clinical trials for Mantle Cell Lymphoma

Study of LUCAR-20S in Patients With R/R NHL

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.

NCT ID: NCT03919175 Terminated - Lymphoma Clinical Trials

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.